Literature DB >> 30890007

Measuring growth of residual cholesteatoma in subtotal petrosectomy.

Catharine A Hellingman1, Joris L E Logher1, Quinten Kammeijer1, Jerome J Waterval1, Fenna A Ebbens1, Erik van Spronsen1.   

Abstract

BACKGROUND: Little is known about the growth rate of cholesteatoma in patients.
OBJECTIVE: Investigate the growth of residual cholesteatoma in subtotal petrosectomy based on volume measured in MRI scans.
MATERIALS AND METHODS: Retrospective case series in a Tertiary Medical Centre. Thirteen residual cholesteatomas were identified in 10 patients after subtotal petrosectomy for which a wait-and-scan policy was adopted. Volume of the residual cholesteatoma was calculated by manual segmentation as well as the 'box method'.
RESULTS: Mean growth rate was 27.9 mm3/month (SD 22.8), with a large individual variation ranging from 2.2 to 69.8 mm3/month. No complications were reported in 10 patients with a wait-and-scan policy for residual cholesteatoma in subtotal petrosectomy. The box method overestimates growth rate compared to the reference method manual segmentation and a linear increase of this systematic error was seen with increasing size of the cholesteatoma.
CONCLUSIONS: Residual cholesteatoma growth rate shows a large individual variation. A wait-and-scan policy could be considered in case of a (small) residual in subtotal petrosectomy with ample room to grow before destroying any remaining structures. Furthermore, the clinically more applicable and less time-consuming box method can be used to accurately measure volumes of small cholesteatomasup to a volume of 500 mm3.

Entities:  

Keywords:  Cholesteatoma; growth; subtotal petrosecomy; volume measurement

Year:  2019        PMID: 30890007     DOI: 10.1080/00016489.2019.1578413

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Surgical results and quality of life after subtotal petrosectomy.

Authors:  Simon Geerse; Rob J de Haan; Fenna A Ebbens; Maarten J F de Wolf; Erik van Spronsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-29       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.